ADVERTISEMENT
TechEconomy
Friday, June 6, 2025
No Result
View All Result
  • News
  • Tech
    • DisruptiveTECH
    • ConsumerTech
      • Accessories
      • Phones
      • Laptop
      • Gadgets and Appliances
      • Apps
    • How To
    • TechTAINMENT
  • Business
    • Telecoms
      • Broadband
    • Mobility
    • Environment
    • Travel
    • Commerce
    • StartUPs
    • TE Insights
    • Security
  • Partners
  • Economy
    • Finance
    • Fintech
    • Digital Assets
    • Personal Finance
    • Insurance
  • Features
    • IndustryINFLUENCERS
    • Guest Writer
    • Appointment
    • EventDIARY
    • Editorial
  • Apply
  • TecheconomyTV
  • Techeconomy Events
  • BusinesSENSE For SMEs
  • TBS
  • News
  • Tech
    • DisruptiveTECH
    • ConsumerTech
      • Accessories
      • Phones
      • Laptop
      • Gadgets and Appliances
      • Apps
    • How To
    • TechTAINMENT
  • Business
    • Telecoms
      • Broadband
    • Mobility
    • Environment
    • Travel
    • Commerce
    • StartUPs
    • TE Insights
    • Security
  • Partners
  • Economy
    • Finance
    • Fintech
    • Digital Assets
    • Personal Finance
    • Insurance
  • Features
    • IndustryINFLUENCERS
    • Guest Writer
    • Appointment
    • EventDIARY
    • Editorial
  • Apply
  • TecheconomyTV
  • Techeconomy Events
  • BusinesSENSE For SMEs
  • TBS
No Result
View All Result
Tech | Business | Economy
No Result
View All Result
Podcast

Home » New AstraZeneca COVID-19 vaccine data further support its use as third dose booster

New AstraZeneca COVID-19 vaccine data further support its use as third dose booster

Yinka Okeowo by Yinka Okeowo
January 14, 2022
in Commerce
1

RelatedPosts

QNET direct selling model

Understanding QNET Direct Selling Business Model  

June 4, 2025

How You Can Get Up to 50% Discount on Konga

June 3, 2025

Positive results from a preliminary analysis of an ongoing safety and immunogenicity trial (D7220C00001) showed that AstraZeneca COVID-19 vaccine (ChAdOx1-S [Recombinant]), when given as a third dose booster, increased the immune response to Beta, Delta, Alpha and Gamma SARS-CoV-2 variants, while a separate analysis of samples from the trial showed increased antibody response to the Omicron variant.

The results were observed among individuals previously vaccinated with either AstraZeneca COVID-19 vaccine or an mRNA vaccine.

A separate Phase IV trial reported in a preprint with The Lancet on SSRN showed that a third dose of AstraZeneca COVID-19 vaccine substantially increased antibody levels following a primary vaccine series with CoronaVac (Sinovac Biotech).

Sir Mene Pangalos, executive vice president, BioPharmaceuticals R&D, AstraZeneca
Advertisements
MTN ADS
Sir Mene Pangalos, executive vice president, BioPharmaceuticals R&D, AstraZeneca

Sir Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said: “AstraZeneca COVID-19 vaccine has protected hundreds of millions of people from COVID-19 around the world and these data show that it has an important role to play as a third dose booster, including when used after other vaccines. Given the ongoing urgency of the pandemic and AstraZeneca COVID-19 vaccine’s increased immune response to the Omicron variant, we will continue to progress regulatory submissions around the world for its use as a third dose booster.”

Professor Sir Andrew J Pollard, chief investigator and director of the Oxford Vaccine Group at the University of Oxford, said: “These important studies show that a third dose of AstraZeneca COVID-19 vaccine after two initial doses of the same vaccine, or after mRNA or inactivated vaccines, strongly boosts immunity against COVID-19. The Oxford-AstraZeneca vaccine is suitable as an option to enhance immunity in the population for countries considering booster programmes, adding to the protection already demonstrated with the first two doses.”

Barbara Nel, Country President, Africa, AstraZeneca, said: ““The latest AstraZeneca COVID-19 vaccine data show the vaccine, when used as a third dose booster, increases the immune response against all variants of concern, including when used after other vaccines. This is of particular importance considering the spread of the Omicron variant. This is really positive news for Sub-Saharan Africa, where over 70M doses of the AstraZeneca COVID-19 vaccine have been supplied, and where countries are striving to attain their vaccination targets and some are beginning to roll out booster programmes.”

The D7220C00001 safety and immunogenicity trial showed that AstraZeneca COVID-19 vaccine continued to be generally well tolerated.

Further analyses from the trial are expected in the first half of 2022.

What is D7220C00001 Trial?

D7220C00001 is an ongoing partially double-blind, randomised, multinational, active-controlled trial in both previously vaccinated and unvaccinated adults to determine the safety and immunogenicity of AstraZeneca COVID-19 vaccine and AZD2816, a vaccine developed for the prevention of COVID-19 caused by the Beta variant of the SARS-CoV-2 virus.

Immunogenicity data for the preliminary analysis were from samples taken 28 days after the third dose booster vaccination.

Individuals included in the preliminary analysis of the trial had been fully vaccinated with two doses of AstraZeneca COVID-19 vaccine (n=700), or an mRNA-based vaccine (n=600), prior to being given a third dose booster vaccination of AstraZeneca COVID-19 vaccine or AZD2816 at least three months after their last injection.

How about RHH-001 Phase IV Trial?

The Phase IV randomized, single-blind, two-centre trial assessed the safety and immunogenicity of a third heterologous booster dose of either AstraZeneca COVID-19 vaccine, an mRNA vaccine (BNT162b2, Pfizer/BioNTech), or a recombinant adenoviral vectored vaccine (AD26.COV2-S, Janssen), compared with a third homologous booster dose of CoronaVac in Brazilian adults who had received two doses of CoronaVac six months previously.

Between 16 August 2021 and 1 September 2021, 1,240 participants were randomised to receive a third dose booster in São Paulo and Salvador, of whom 1,239 were vaccinated.

The primary outcome of the trial was non-inferiority of anti-spike IgG antibodies 28 days after the booster dose in the heterologous boost groups compared with homologous regimen.

Vaxzevria, (ChAdOx1-S [Recombinant], formerly AZD1222)

Vaxzevria (AstraZeneca COVID-19 vaccine) was invented by the University of Oxford. It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein.

After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.

The vaccine has been granted a conditional marketing authorisation or emergency use in more than 90 countries. It also has Emergency Use Listing from the World Health Organization, which accelerates the pathway to access in up to 144 countries through the COVAX Facility.

Under a sub-license agreement with AstraZeneca, the vaccine is manufactured and supplied by the Serum Institute of India under the name COVISHIELD.

More about AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Loading

Author

  • Yinka Okeowo
    Yinka Okeowo

    View all posts
0Shares
Tags: AstraZeneca COVID-19 Coronavirus Vaccine for Omicron boosterAstraZeneca COVID-19 vaccine
Previous Post

Nigerian healthcare providers still use medical equipment with legacy Operating Systems

Next Post

How B2B e-commerce consolidates Nigeria’s digital economy blueprint

Yinka Okeowo

Yinka Okeowo

Related Posts

QNET direct selling model
Commerce

Understanding QNET Direct Selling Business Model  

by Techeconomy
June 4, 2025
0

As individuals, we can all relate to recommending products we have used, liked and enjoyed to our family, friends and...

Read more
50% Discount on kOnga

How You Can Get Up to 50% Discount on Konga

June 3, 2025
Jumia Transforms Customer Experience with Sprinklr’s AI-Powered Platform | 13 Years

Jumia Marks 13 Years of e-Commerce Innovation in Nigeria

June 3, 2025
Nigeria NATEP

Nigeria Relaunches National Talent Export Programme (NATEP) to Unlock $1 Trillion Global Outsourcing Market

June 2, 2025
U.S., China Slash Tariffs in Surprise 90-Day Truce, Resetting Trade Divide

Why U.S. Tariffs Won’t Derail China’s Global Strategy

June 1, 2025
td africa Black Friday

Every Friday is Black Friday: TD Africa Turns Up the Heat on Tech Accessibility

May 27, 2025
Next Post

How B2B e-commerce consolidates Nigeria’s digital economy blueprint

Comments 1

  1. Pingback: AstraZeneca to Take its HHA Programme to 10 More Countries in Africa - TechEconomy Nigeria

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

I agree to the Terms & Conditions and Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Techeconomy Podcast

Techeconomy Podcast
Techeconomy Podcast

Infowave is brought to you by TechEconomy. Every week we will bring new stories from startups and influencers who are shaping and changing the world we live in. We’ll also bring you reports on topics you should know.

Follow us @techeconomyng for more.

TECH TALK EPISODE 2
byTecheconomy

PRODUCTIVITY AND WORK-Life Balance

TECH TALK EPISODE 2
TECH TALK EPISODE 2
May 22, 2025
Techeconomy
CYBERSECURITY ESSENTIALS
April 24, 2025
Techeconomy
Digital Marketing Trends and strategies for 2025 and beyond
February 27, 2025
Techeconomy
Major Lesson for Techies in 2024 and Projections for 2025
December 6, 2024
Techeconomy
Major Lessons for Techies in an AI-Driven World | Techeconomy Business Series Highlights
November 26, 2024
Techeconomy
Maximizing Profitability Through Seasonal Sales: Strategies For Success
November 8, 2024
Techeconomy
Techeconomy Business Series
October 15, 2024
Techeconomy
PRIVACY IN THE ERA OF AI: GETTING YOUR BUSINESS READY
May 30, 2024
Techeconomy
Unravel the Secrets of Marketing Everywhere All At Once with Isaac Akanni from Infobip | Infowave Podcast Episode 1
February 9, 2024
Techeconomy
The Role of Ed-tech in Life Long Learning and Continuous Education
October 19, 2023
Techeconomy
Search Results placeholder

WHAT IS TRENDING

https://www.youtube.com/watch?v=g_MCUwS2woc&list=PL6bbK-xx1KbIgX-IzYdqISXq1pUsuA4dz

Follow Us

  • About Us
  • Contact Us
  • Careers
  • Privacy Policy

© 2025 Techeconomy - Designed by Opimedia.

No Result
View All Result
  • News
  • Tech
    • DisruptiveTECH
    • ConsumerTech
      • Accessories
      • Phones
      • Laptop
      • Gadgets and Appliances
      • Apps
    • How To
    • TechTAINMENT
  • Business
    • Telecoms
      • Broadband
    • Mobility
    • Environment
    • Travel
    • Commerce
    • StartUPs
    • TE Insights
    • Security
  • Partners
  • Economy
    • Finance
    • Fintech
    • Digital Assets
    • Personal Finance
    • Insurance
  • Features
    • IndustryINFLUENCERS
    • Guest Writer
    • Appointment
    • EventDIARY
    • Editorial
  • Apply
  • TecheconomyTV
  • Techeconomy Events
  • BusinesSENSE For SMEs
  • TBS

© 2025 Techeconomy - Designed by Opimedia.

Translate »
This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.